New Results from Phase II ARB-1467 Multi-Dosing Study In September 2016, Arbutus reported single
dose ARB-1467 results for Cohorts 1 (0.2mg/kg) and 2 (0.4 mg/kg) and multiple
dose results from Cohort 1 (Cohorts 1 and 2 enrolled HBeAg- patients). Today Arbutus is reporting multiple dose results from Cohort 2, which show a significant reduction in HBsAg. In both Cohort 1 and Cohort 2, an additive, step-wise reduction in HBsAg was observed with each dose.